You are here

cancer

First of its Kind “Universal” Immune Cell Cancer Therapy

First of its Kind “Universal” Immune Cell Cancer Therapy

Xtalks

prostate cancer

Cardiff University

Flag link:

Merck KGaA spinout iOnctura raises cash for cancer trials

Merck KGaA spinout iOnctura raises cash for cancer trials

Fierce Biotech

clinical trials

Flag link:

Almost 50 Non-Oncology Drugs Found to Kill Cancer Cells

Almost 50 Non-Oncology Drugs Found to Kill Cancer Cells

BioSpace

Broad Institute

drug repurposing

Flag link:

BeiGene lung cancer treatment meets main goal in late-stage study

BeiGene lung cancer treatment meets main goal in late-stage study

Reuters

clinical trials

Flag link:

I Have a Dream… Five Dreams for Biotech

I Have a Dream… Five Dreams for Biotech

BioSpace

Alzheimer's disease

Flag link:

JPM: Biotech, VC execs on where the industry should look beyond cancer

JPM: Biotech, VC execs on where the industry should look beyond cancer

Fierce Biotech

Alzheimer's disease

venture capital

Flag link:

After closing one of China's biggest-ever raises, I-Mab Biopharma nabs $104M Nasdaq IPO

After closing one of China's biggest-ever raises, I-Mab Biopharma nabs $104M Nasdaq IPO

Fierce Biotech

I-Mab Biopharma

autoimmune disease

Flag link:

Tumour-agnostic drugs ‘game-changing’, says NICE as it rejects one from Bayer

Tumour-agnostic drugs ‘game-changing’, says NICE as it rejects one from Bayer

Pharmaforum

Flag link:

Why Johnson & Johnson Will Survive its Latest Litigation Wave

Why Johnson & Johnson Will Survive its Latest Litigation Wave

Motley Fool

Flag link:

FDA Warns of Potential Cancer Risk With Weight Loss Drug

FDA Warns of Potential Cancer Risk With Weight Loss Drug

RAPS.org

Flag link:

Pfizer and eFFECTOR Ink $507 Million Cancer Deal

Pfizer and eFFECTOR Ink $507 Million Cancer Deal

BioSpace

small molecule drugs

drug development

Flag link:

At 2020 deadline, progress in Patrick Soon-Shiong’s ‘cancer moonshot’ is hard to find

At 2020 deadline, progress in Patrick Soon-Shiong’s ‘cancer moonshot’ is hard to find

Stat

Dr. Patrick Soon-Shiong

clinical trials

Flag link:

US cancer death rate drops by sharpest rate on record

US cancer death rate drops by sharpest rate on record

BioPharma Dive

Bristol-Myers Squibb

Flag link:

Verastem pens KRAS-focused drug licensing deal with Chugai

Verastem pens KRAS-focused drug licensing deal with Chugai

Fierce Biotech

Flag link:

Drug developers take fresh aim at 'guided-missile' cancer drugs

Drug developers take fresh aim at 'guided-missile' cancer drugs

Reuters

drug development

antibody-drug conjugate

Flag link:

The first biotech IPO of the new decade has landed — and of course it's another cancer drug developer

The first biotech IPO of the new decade has landed — and of course it's another cancer drug developer

Endpoints

Black Diamond Therapeutics

I-Mab Biopharma

Flag link:

3 Blockbuster Cancer Drug Launches to Watch in 2020

3 Blockbuster Cancer Drug Launches to Watch in 2020

Motley Fool

Seattle Genetics

Flag link:

Takeda Strikes Potential $1 Billion Oncology Deal with Turnstone

Takeda Strikes Potential $1 Billion Oncology Deal with Turnstone

BioSpace

Turnstone Biologics

Flag link:

When FDA Requires Pediatric Studies for New Cancer Drug Submissions: New Draft Guidance

When FDA Requires Pediatric Studies for New Cancer Drug Submissions: New Draft Guidance

RAPS.org

pediatric cancer

Flag link:

Vedanta Biosciences initiates first-in-patient study of VE800 in combination with Bristol-Myers Squibb’s Opdivo

Vedanta Biosciences initiates first-in-patient study of VE800 in combination with Bristol-Myers Squibb’s Opdivo

Pharmaceutical Business Review

Vedanta Biosciences

Bristol-Myers Squibb

clinical trials

Flag link:

Pages